To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Classification of clear c… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Contact form








 


Note! If you want an answer on a question you must specify your email address




Classification of clear cell renal cell carcinoma based on PKM alternative splicing

Journal article
Authors X. Y. Li
B. Turanli
K. Juszczak
W. Kim
M. Arif
Y. Sato
S. Ogawa
H. Turkez
J. Nielsen
Jan Borén
M. Uhlen
C. Zhang
A. Mardinoglu
Published in Heliyon
Volume 6
Issue 2
Pages 10
ISSN 2405-8440
Publication year 2020
Published at Institute of Medicine, Department of Molecular and Clinical Medicine
Pages 10
Language en
Links dx.doi.org/10.1016/j.heliyon.2020.e...
Keywords Bioinformatics, Cancer research, Systems biology, PKM, Alternative, splicing, Transcriptomics, Biomarker, Drug repositioning, pyruvate-kinase m2, isoform expression, cancer metabolism, bile-acids, signatures, migration, angiogenesis, progression, modulation, invasion, Science & Technology - Other Topics
Subject categories Clinical Medicine

Abstract

Clear cell renal cell carcinoma (ccRCC) accounts for 70-80% of kidney cancer diagnoses and displays high molecular and histologic heterogeneity. Hence, it is necessary to reveal the underlying molecular mechanisms involved in progression of ccRCC to better stratify the patients and design effective treatment strategies. Here, we analyzed the survival outcome of ccRCC patients as a consequence of the differential expression of four transcript isoforms of the pyruvate kinase muscle type (PKM). We first extracted a classification biomarker consisting of eight gene pairs whose within-sample relative expression orderings (REOs) could be used to robustly classify the patients into two groups with distinct molecular characteristics and survival outcomes. Next, we validated our findings in a validation cohort and an independent Japanese ccRCC cohort. We finally performed drug repositioning analysis based on transcriptomic expression profiles of drug-perturbed cancer cell lines and proposed that paracetamol, nizatidine, dimethadione and conessine can be repurposed to treat the patients in one of the subtype of ccRCC whereas chenodeoxycholic acid, fenoterol and hexylcaine can be repurposed to treat the patients in the other subtype.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?